Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies

Critical Reviews in Oncology/Hematology

Volumn 58, Issue 3, 2006, Pages 242-256

  Gadducci, Angiolo ^a   Cosio, Stefania ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Chemotherapy; Clostridium perfringens enterotoxin; Endometrial cancer; Endometrioid carcinoma; Hormonal therapy; Mammalian target of the rapamycin mTOR ; Trastuzumab; Tyrosine kinase inhibitors; Uterine serous papillary carcinoma

Indexed keywords

ADENOVIRUS VECTOR; AP 23573; AROMATASE INHIBITOR; ARZOXIFENE; CARBOPLATIN; CCI 799; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENTEROTOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GESTAGEN; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HYDROXYPROGESTERONE CAPROATE; IGW 572016; IMATINIB; LAPATINIB; LETROZOLE; LEUPRORELIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE ACETATE; PACLITAXEL; PROGESTERONE; PROGESTERONE RECEPTOR; RAPAMYCIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIVITY; CHRONOTHERAPY; CLINICAL TRIAL; CLOSTRIDIUM PERFRINGENS; DATA ANALYSIS; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; ENDOMETRIUM CANCER; HISTOLOGY; HUMAN; INTRACELLULAR SPACE; MENOPAUSAL SYNDROME; METASTASIS; MOLECULAR DYNAMICS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NEURALGIA; NONHUMAN; OVARY CARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; RECEPTOR DOWN REGULATION; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TISSUE SPECIFICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERUS CARCINOMA; VIRAL GENE THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; CLINICAL TRIALS, PHASE III; CYSTADENOCARCINOMA, PAPILLARY; DRUG DESIGN; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; SIGNAL TRANSDUCTION;

EID: 33646934663     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.11.002     Document Type: Review

References (175)

1. Matias-Guiu X., Catasus L., Bussaglia E., et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32 (2001) 569-577
2. Creasman W.T., Odicino F., Massoineuve P., et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 6 (2001) 45-86
3. Bremond A., Bataillard A., Thomas L., et al. Standards, options and recommendations for the surgical management of carcinoma of the endometrium. Bull Cancer 88 (2001) 181-198
4. Santin A.D., Bellone S., O'Brien T.J., Pecorelli S., Cannon M.J., and Roman J.J. Current treatment options for endometrial cancer. Expert Rev Anticancer Ther 4 (2004) 679-689
5. Boronow R.C. Surgical staging of endometrial cancer: evolution, evaluation, and responsible challenge-a personal perspective. Gynecol Oncol 66 (1997) 179-189
6. Gadducci A., Cosio S., and Genazzani A.R. Treatment planning in endometrial cancer. Cancer Therapy 1 (2003) 373-391
7. Kilgore L.C., Partridge E.E., Alvarez R.D., et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56 (1995) 29-33
8. Onda T., Yoshikawa H., Mizutani K., et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 75 (1997) 1836-1841
9. Benedetti Panici P., Maneschi F., Cutillo G., D'Andrea G., Manci N., and Rabitti C. Anatomical and pathological study of retroperitoneal nodes in endometrial cancer. Int J Gynecol Cancer 8 (1998) 322-327
10. Mariani A., Webb M.J., Galli L., and Podratz K.C. Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 76 (2000) 348-356
11. Candiani G.B., Belloni C., Maggi R., Colombo G., Frigoli A., and Carinelli S.G. Evaluation of different surgical approaches in the treatment of endometrial cancer at FIGO stage I. Gynecol Oncol 37 (1990) 6-8
12. Massi G., Savino L., and Susini T. Vaginal hysterectomy versus abdominal hysterectomy for the treatment of stage I endometrial adenocarcinoma. Am J Obstet Gynecol 174 (1996) 1320-1326
13. Cragun J.M., Havrilesky L.J., Calingaert B., et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23 (2005) 3668-3675
14. Sartori E., Gadducci A., Landoni F., et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer 11 (2001) 430-437
15. Mariani A., Webb M.J., Keeney G.L., Calori G., and Podratz K.C. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol 83 (2001) 72-80
16. Susini T., Massi G., Amunni G., et al. Vaginal hysterectomy and abdominal hysterectomy for treatment of endometrial cancer in the elderly. Obstet Gynecol Surv 60 (2005) 302-303
17. Chu C.S., Randall T.C., Bandera C.A., and Rubin S.C. Vaginal cuff recurrence of endometrial cancer treated by laparoscopic-assisted vaginal hysterectomy. Gynecol Oncol 88 (2003) 62-65
18. Tozzi R., Malur S., Koehler C., and Schneider A. Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study. J Minim Invasive Gynecol 12 (2005) 130-136
19. Bristow R.E., Zerbe M.J., Rosenshein N.B., Grumbine F.C., and Montz F.J. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 78 (2000) 85-91
20. Bristow R.E., Duska L.R., and Montz F.J. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 81 (2001) 92-99
21. Cirisano Jr. F.D., Robboy S.J., Dodge R.K., et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77 (2000) 55-65
22. Chan J.K., Loizzi V., Youssef M., et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 90 (2003) 181-185
23. Creutzberg C.L., van Putten W.L., Koper P.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 (2000) 1404-1411
24. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 744-751
25. Corn B.W., Lanciano R.M., Greven K.M., et al. Endometrial cancer with para-aortic adenopathy: patterns of failure and opportunities for cure. Int J Radiat Oncol Biol Phys 24 (1992) 223-227
26. Sood B.M., Timmins P.F., Gorla G.R., et al. Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer. Int J Gynecol Cancer 12 (2002) 459-464
27. McMeekin D.S., and Tillmanns T. Endometrial cancer: treatment of nodal metastases. Curr Treat Options Oncol 4 (2003) 121-130
28. Slomovitz B.M., Wolf J., Ramondetta L.M., Burke T.W., and Lu K.H. Advances in the management of advanced and recurrent uterine papillary serous carcinoma. Int J Gynecol Cancer 15 (2005) 406
29. Duska L.R., Berkowitz R., Matulonis U., et al. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol 96 (2005) 198-203
30. Huh W.K. What is the correct management of stage I UPSC?. Int J Gynecol Cancer 15 (2005) 405-406
31. Thigpen J.T., Brady M.F., Alvarez R.D., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17 (1999) 1736-1744
32. Dows Jr. L.S., and Boente M.P. Uterine carcinomas: chemotherapy of primary and recurrent tumors. In: Angioli R., Benedetti Panici P., Kavanagh J.J., Pecorelli S., and Penalver M. (Eds). Chemotherapy for gynaecological neoplasms. Current therapy and novel approaches (2004), Marcel Dekker, Inc., New York 519-527
33. Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer 41 (2005) 673-675
34. McMeekin D.S. Updates in chemotherapy in the treatment of advanced and recurrent endometrial cancer. Int J Gynecol Cancer 15 (2005) 407-408
35. Jhingran A., Burke T.W., and Eifel P.J. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 56 (2003) 1366-1372
36. Chi D.S., and Barakat R.R. Surgical management of advanced or recurrent endometrial cancer. Surg Clin N Am 81 (2001) 885-896
37. Campagnutta E., Giorda G., De Piero G., et al. Surgical treatment of recurrent endometrial carcinoma. Cancer 100 (2004) 89-96
38. Kew F.M., Roberts A.P., and Cruickshank D.J. The role of routine follow-up after gynecological malignancy. Int J Gynecol Cancer 15 (2005) 413-419
39. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observation Acta Obstet. Gynecol Scand 63 (1984) 441-450
40. Piver M.S., Barlow J.J., Lurain J.R., and Blumenson L.E. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45 (1980) 268-272
41. Podratz K.C., O'Brien P.C., Malkasian Jr. G.D., Decker D.G., Jefferies J.A., and Edmonson J.H. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66 (1985) 106-110
42. Cavalli F., Goldhirsch A., Jungi F., Martz G., Mermillod B., and Alberto P. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2 (1984) 414-419
43. Thigpen T., Brady M.F., Homesley H.D., Soper J.T., and Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 15 (2001) 364-367
44. Pandya K.J., Yeap B.Y., Weiner L.M., et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 24 (2001) 43-46
45. Whitney C.W., Brunetto V.L., Zaino R.J., et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 4-9
46. Fiorica J.V., Brunetto V.L., Hanjani P., Lentz S.S., Mannel R., and Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 10-14
47. Dai D., Albitar L., Nguyen T., Laidler L.L., Singh M., and Leslie K.K. A therapeutic model for advanced endometrial cancer: systemic progestin in combination with local adenoviral-mediated progesterone receptor expression. Mol Cancer Ther 4 (2005) 169-175
48. Jeyarajah A.R., Gallagher C.J., Blake P.R., et al. Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol 63 (1996) 47-52
49. Covens A., Thomas G., Shaw P., et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 64 (1997) 126-129
50. Asbury R.F., Brunetto V.L., Lee R.B., Reid G., and Rocereto T.F. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 25 (2002) 557-560
51. Nagai N., Oshita T., Mukai K., Shiroyama Y., Shigemasa K., and Ohama K. GnRH agonist inhibits human telomerase reverse transcriptase mRNA expression in endometrial cancer cells. Int J Mol Med 10 (2002) 593-597
52. Engel J.B., Keller G., Schally A.V., Toller G.L., et al. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab 90 (2005) 3614-3621
53. Rose P.G., Brunetto V.L., VanLe L., Bell J., Walker J.L., and Lee R.B. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78 (2000) 212-216
54. Berstein L., Maximov S., Gershfeld E., et al. Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. Eur J Obstet Gynecol Reprod Biol 105 (2002) 161-165
55. Gadducci A., Cosio S., and Genazzani A.R. Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Investig Drugs 5 (2004) 1031-1044
56. Ma B.B., Oza A., Eisenhauer E., et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14 (2004) 650-658
57. Burke T.W., and Walker C.L. Arzoxifene as therapy for endometrial cancer. Gynecol Oncol 90 (2003) S40-S46
58. McMeekin D.S., Gordon A., Fowler J., et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 90 (2003) 64-69
59. Orejuela F.J., Ramondetta L.M., Smith J., et al. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol Oncol 97 (2005) 483-488
60. Horton J., Begg C.B., Arseneault J., Bruckner H., Creech R., and Hahn R.G. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 62 (1978) 159-161
61. Thigpen J.T., Blessing J.A., DiSaia P.J., Yordan E., Carson L.F., and Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 12 (1994) 1408-1414
62. Muss H.B. Chemotherapy of metastatic endometrial cancer. Semin Oncol 21 (1994) 107-113
63. Thigpen J.T., Brady M.F., Homesley H.D., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22 (2004) 3902-3908
64. Thigpen T., Vance R.B., and Khansur Y. The platinum compounds in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 22 Suppl 12 (1995) 67-75
65. Tropè C., and Kristensen G. Current status of chemotherapy in gynecologic cancer. Semin Oncol 24 (1997) S15-S22
66. Edmondson J.H., Krook J.E., Hilton J.F., et al. Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol 28 (1987) 20-24
67. Thigpen J.T., Blessing J.A., Homesley H., Creasman W.T., and Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 33 (1989) 68-70
68. Calero F., Asins-Codoner E., Jimeno J., et al. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO). Eur J Cancer 27 (1991) 864-866
69. Long H.J., Pfeifle D.M., Wieand H.S., Krook J.E., Edmonson J.H., and Buckner J.C. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 80 (1988) 276-278
70. Green III J.B., Green S., Albert D.S., O'Toole R., Surwit E.A., and Noltimier J.W. Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 75 (1990) 696-700
71. Burke T.W., Munkarah A., Kavanagh J.J., et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51 (1993) 397-400
72. van Wijk F.H., Lhomme C., Bolis G., et al. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 39 (2003) 78-85
73. Sutton G.P., Blessing J.A., DeMars L.R., Moore D., Burke T.W., and Grendys E.C. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 63 (1996) 25-27
74. Holloway R.W. Treatment options for endometrial cancer: experience with topotecan. Gynecol Oncol 90 (2003) S28-S33
75. Wadler S., Levy D.E., Lincoln S.T., Soori G.S., Schink J.C., and Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol 21 (2003) 2110-2114
76. Ball H.G., Blessing J.A., Lentz S.S., and Mutch D.G. A phase II trial of taxol in advanced and recurrent adenocarcinoma of the endometrium. Gynecol Oncol 62 (1996) 278-281
77. Lissoni A., Zanetta G., Losa G., Gabriele A., Parma G., and Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 7 (1996) 861-863
78. Woo H.L., Swenerton K.D., and Hoskins P.J. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 19 (1996) 290-291
79. Lincoln S., Blessing J.A., Lee R.B., and Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88 (2003) 277-281
80. Hirai Y., Hasumi K., Onose R., et al. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. Gynecol Oncol 94 (2004) 471-476
81. Gunthert A.R., Ackerman S., Kiesel L., et al. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer, AGO Uterus-4. Proc Am Soc Clin Oncol 23 (2005) 5083 [abstract]
82. Muggia F.M., Blessing J.A., Sorosky J., and Reid G.C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 20 (2002) 2360-2364
83. Escobar P.F., Markman M., Zanotti K., Webster K., and Belinson J. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol 129 (2003) 651-654
84. Muggia F.M., Chia G., Reed L.J., and Romney S.L. Doxorubicin-cyclophosphamide: effective chemotherapy for advanced endometrial adenocarcinoma. Am J Obstet Gynecol 128 (1977) 314-319
85. Seski J.C., Edwards C.L., Gershenson D.M., and Copeland L.J. Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer. Obstet Gynecol 58 (1981) 88-91
86. Campora E., Vidali A., Mammoliti S., Ragni N., and Conte P.F. Treatment of advanced or recurrent adenocarcinoma of endometrium with doxorubicin and cyclophosphamide. Eur J Gynaecol Oncol 11 (1990) 181-183
87. Trope C., Johnsson J.E., Simonsen E., Christiansen H., Cavallin-Stahl E., and Horvath G. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol 149 (1984) 379-381
88. Aapro M.S., van Wijk F.H., Bolis G., et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14 (2003) 441-448
89. Gallion H.H., Brunetto V.L., Cibull M., et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 21 (2003) 3808-3813
90. Lovecchio J.L., Averette H.E., Lichtinger M., Townsend P.A., Girtanner R.W., and Fenton A.N. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-platinum, and megestrol acetate. Obstet Gynecol 63 (1984) 557-560
91. Dunton C.J., Pfeifer S.M., Braitman L.E., Morgan M.A., Carlson J.A., and Mikuta J.J. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin and cyclophosphamide. Gynecol Oncol 41 (1991) 113-116
92. Burke T.W., Stringer C.A., Morris M., et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 40 (1991) 264-267
93. Gadducci A., Romanini A., Cosio S., et al. Combination of cisplatin, epirubicin, and cyclophoshamide (PEC regimen) in advanced or recurrent endometrial cancer: a retrospective clinical study. Anticancer Res 19 (1999) 2253-2256
94. Levin L., and Hryniuk W. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 14 Suppl 4 (1987) 12-19
95. Randal M.E., Brunetto G., Muss H., et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomised phase III trial of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 22 (2003) 3 [abstract]
96. Mundt A.J., McBride R., Rotmensch J., Waggoner S.E., Yamada S.D., and Connell P.P. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 1145-1153
97. Soper J.T., Reisinger S.A., Ashbury R., Jones E., and Clarke-Pearson D.L. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial. Gynecol Oncol 95 (2004) 95-100
98. Chang S.J., Chen T.C., Wang T.Y., Hsu C.Y., Chen H.S., and Yang Y.C. Successful treatment with weekly paclitaxel in a patient with recurrent endometrial cancer. A case report. Eur J Gynaecol Oncol 24 (2003) 377-378
99. Markman M., and Fowler J. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol Oncol 92 (2004) 180-182
100. Fleming G.F., Filiaci V.L., Bentley R.C., et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 15 (2004) 1173-1178
101. Lissoni A., Gabriele A., Gorga G., et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 8 (1997) 969-972
102. Fleming G.F., Brunetto V.L., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22 (2004) 2159-2166
103. Hoskins P.J., Swenerton K.D., Pike J.A., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19 (2001) 4048-4053
104. Scudder S.A., Liu P.Y., Wilczynski S.P., et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol 96 (2005) 610-615
105. Sovak M.A., Chuai A., Anderson S., et al. Paclitaxel and carboplatin (TP) for treatment of advanced or recurrent endometrial cancer: a retrospective study. Proc Am Soc Clin Oncol 23 (2005) 5020 [abstract]
106. Akram T., Maseelall P., and Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 192 (2005) 1365-1367
107. Michener C.M., Peterson G., Kulp B., Webster K.D., and Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol 131 (2005) 581-584
108. Eltabbakh G.H., Moody J., Garafano L.L., and Hammond J.M. The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma. Eur J Gynaecol Oncol 20 (1999) 18-19
109. Le T.D., Yamada S.D., Rutgers J.L., and DiSaia P.J. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. Gynecol Oncol 73 (1999) 461-463
110. Nicklin J.L., and Copeland L.J. Endometrial papillary serous carcinoma: pattern of spread and treatment. Clin Obstet Gynecol 39 (1996) 686-695
111. Brader S., and Eccles S.A. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90 (2004) 2-8
112. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
113. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22 (2004) 2954-2963
114. Osaki M., Oshimura M., and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9 (2004) 667-676
115. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
116. Brunet A., Bonni A., Zigmond M.J., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
117. Mak B.C., and Yeung R.S. The tuberous sclerosis complex genes in tumor development. Cancer Invest 22 (2004) 588-603
118. Gingras A.C., Kennedy S.G., O'Leary M.A., Sonenberg N., and Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12 (1998) 502-513
119. Huang S., and Houghton P.J. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3 (2003) 371-377
120. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16 (2004) 564-575
121. Xu G., Zhang W., Bertram P., Zheng X.F., and McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24 (2004) 893-900
122. Dutcher J.P. Mammalian target of rapamycin inhibition. Clin Cancer Res 10 18 Pt 2 (2004) 6382S-6387S
123. Dudkin L., Dilling M.B., Cheshire P.J., et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7 (2001) 1758-1764
124. 1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273 (1998) 14424-14429
125. De Benedetti A., and Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 23 (2004) 3189-3199
126. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92 (2000) 924-930
127. An H.J., Lee Y.H., Cho N.H., Shim J.Y., Kim J.Y., Lee C., et al. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 41 (2002) 437-445
128. Terakawa N., Kanamori Y., and Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocrinol Relat Cancer 10 (2003) 203-208
129. Slomovitz M.B., Wu W., Broaddus R.R., et al. mTOR inhibition is a rational target for the treatment of endometrial cancer. Proc Am Soc Clin Oncol 22 (2004) 5076 [abstract]
130. Soliman P.T., Schmeler K.M., Broaddus R.R., et al. mTOR inhibition as a potential treatment for progesterone refractory endometrial hyperplasia. Proc Am Soc Clin Oncol 23 (2005) 5080 abstract
131. Rao R.D., Buckner J.C., and Sarkaria J.N. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 4 (2004) 621-635
132. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91 (2004) 1420-1424
133. Peralba J.M., deGraffenried L., Friedrichs W., et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9 (2003) 2887-2892
134. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16 (2005) 525-537
135. Dancey J.E. Inhibitors of the mammalian target of rapamycin. Expert Opin Invest Drugs 14 (2005) 313-328
136. Zhou C., Gehrig P.A., Whang Y.E., and Boggess J.F. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2 (2003) 789-795
137. Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., and Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62 (2002) 6141-6145
138. Mondesire W.H., Jian W., Zhang H., et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10 (2004) 7031-7042
139. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747-759
140. Punt C.J., Boni J., Bruntsch U., Peters M., and Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14 (2003) 931-937
141. Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. Drugs R&D 5 (2004) 363-367
142. Boni J.P., Leister C., Bender G., et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77 (2005) 76-89
143. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 (2004) 2336-2347
144. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
145. Newton H.B. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2. PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 4 (2004) 105-128
146. Panwalkar A., Verstovsek S., and Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100 (2004) 657-666
147. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 24 (2002) 53-58
148. Mita M.M., Mita A., and Rowinski E.K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 4 (2003) 126-137
149. Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64 (2004) 252-261
150. O'Donnell A., Faivre S., Judson I., et al. A phase I study of the oral mTOR inhibitors RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetics (PK) and pharmacodinamic (PD) endpoints in patients with solid tumours. Proc Am Soc Clin Oncol 22 (2003) 803 [abstract]
151. Wolf J., and Slomovitz B.M. Novel biologic therapies for the treatment of endometrial cancer. Int J Gynecol Cancer 15 (2005) 411
152. Desai A.A., Mita M., Fetterly G.J., et al. Development of a pharmacokinetic (PK) model and assessment of patients (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I-trials of AP23573(AP), a mTOR inhibitor. Proc Am Soc Clin Oncol 23 (2005) 3043 [abstract]
153. Mita M.M., Rowinsky E.K., Goldston M.L., et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. Proc Am Soc Clin Oncol 22 (2004) 3076 [abstract]
154. Rivera V.M., Kreisinger J.I., Mita M.M., et al. Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. Proc Am Soc Clin Oncol 23 (2005) 3033 [abstract]
155. Feldman E., Giles F., Roboz G., et al. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. Proc Am Soc Clin Oncol 23 (2005) 6631 [abstract]
156. Chawla S.P., Sankala K.K., Chua V., et al. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. Proc Am Soc Clin Oncol 23 (2005) 9068 [abstract]
157. Janish L.A., Desai A.A., Mita M., et al. PTEN expression in archivial tumor samples in patients (pts) with advanced malignancies in two phase I studies of AP23573 (AP), an mTOR inhibitor. Proc Am Soc Clin Oncol 23 (2005) 9661 [abstract]
158. Leslie K.K., Laidler L., Albitar L., et al. Tyrosine kinase inhibitors in endometrial cancer. Int J Gynecol Cancer 15 (2005) 409-411
159. Jasa K.V., Fyles A., Elit L., et al. Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148. Proc Am Soc Clin Oncol 22 (2004) 5019 [abstract]
160. Janne P.A., Engelman J.A., and Johnson B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23 (2005) 3227-3234
161. Wiedmann M.W., and Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 5 (2005) 171-193
162. Capdeville R., Silberman S., and Dimitrijevic S. Imatinib: the first 3 years. Eur J Cancer 38 Suppl 5 (2002) S77-S82
163. Slomovitz B.M., Broaddus R.R., Schmandt R., et al. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol 95 (2004) 32-36
164. Santin A.D., Bellone S., Gokden M., et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8 (2002) 1271-1279
165. Villella J.A., Cohen S., Tiersten A., Smith D.H., Hibshoosh H., and Hershman D. Her2/neu expression in uterine papillary serous cancers. Proc Am Soc Clin Oncol 22 (2003) 1870 [abstract]
166. Santin A.D., Zhan F., Bellone S., et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumors by gene expression profiling. Br J Cancer 90 (2004) 1814-1824
167. Slomovitz B.M., Broaddus R.R., Burke T.W., et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22 (2004) 3126-3132
168. Santin A.D., Zhan F., Cane' S., et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 92 (2005) 1561-1573
169. Santin A.D., Bellone S., Siegel E.R., et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol 192 (2005) 813-818
170. De Laurentiis M., Cancello G., Zinno L., et al. Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann Oncol 16 Suppl 4 (2005) 7-13
171. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., and Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21 (2003) 283-290
172. Katahira J., Sugiyama H., Inoue N., Horiguchi Y., Matsuda M., and Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem 272 (1997) 26652-26658
173. McClane B.A. An overview of Clostridium perfringens enterotoxin. Toxicon 34 (1996) 1335-1343
174. Long H., Crean C.D., Lee W.H., Cummings O.W., and Gabig T.G. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 61 (2001) 7878-7881
175. Michl P., Buchholz M., Rolke M., et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121 (2001) 678-684